Apraxia Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2023

 The Americas dominate the global apraxia market owing to well-developed technology, increasing prevalence of neurological disorders, high health care spending, and increasing government support for research & development. Furthermore, increasing R&D activities and the presence of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global apraxia market. The government support for research & development and availability of funds for research are projected to drive the market in Europe region over the review period. 

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/4872

Asia Pacific is the fastest growing apraxia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing new opportunities in countries like China, India, Japan, and South Korea will make this as emerging and the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is likely to lead the use of advanced equipment, which, in turn, will increase the growth of the market in the region.

The global apraxia market is expected to grow at a CAGR of ~ 6.4 % during the forecast period 2017-2023.

On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.

Apraxia is a neurological condition. Also, it is known as a motor disorder caused by damage to the brain. In this case, patients who find it difficult or impossible to make certain motor movements, even though their muscles are normal. Apraxia can occur in different forms one of which is orofacial apraxia. In which, patients are unable to voluntarily perform certain movements involving facial muscles. For instance, they may not be able to wink. Another form of apraxia affects a patient’s ability to intentionally move arms and legs.

Whereas in children apraxia of speech (CAS) has a number of possible causes, but in many cases, the cause can’t be determined and often don’t observe a problem in the brain of a child with CAS. CAS may be the result of brain (neurological) conditions or injuries, such as a stroke, infections or traumatic brain injury.

The apraxia market growth is majorly attributed to the increasing prevalence of neurological disorders, increasing investment of biotechnology and pharmaceutical industries in R&D, and rising need for the better treatment methods drive the growth of the market. Moreover, favorable reimbursement policies, increased application and significant investments in the development of new technologies for the treatment of various neurological diseases are likely to fuel the market growth during the forecast period.

According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high-income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

However, the high cost of this treatment procedure may hamper the market growth during the corresponding period.

Key Players

Some of key the players in the market are Medtronic Plc., Codman & Shurtleff, Inc., Raumedic AG, Vittamed, Sophysa Ltd., MicroPort Scientific Corporation, Orsan Medical Technologies, Spiegelberg GmbH, Johnson & Johnson, Sophysa Ltd, HaiWeiKang, Head Sense Medical, InfraScan, Inc., Integra Life Sciences Corporation and others.

Segmentations

The global apraxia market has been segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of the types, the market is segmented into ideomotor apraxia, ideational/conceptual apraxia, buccofacial or orofacial apraxia, constructional apraxia, gait apraxia, limb-kinetic apraxia, oculomotor apraxia, apraxia of speech.

On the basis of the diagnosis, the market is segmented into a test to measure upper limb apraxia, MRI, and others.

On the basis of the treatment, the market is segmented into speech therapy, occupational therapy, physical therapy, and others.

On the basis of the ‘end user, the market is segmented into hospitals & clinics, research centers, and others.

Browse for more details @ https://www.marketresearchfuture.com/reports/apraxia-market-4872

The Carcinoid Tumor Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

 

Market Highlights

Carcinoid tumor is a type of the neuroendocrine tumor. The most common site of carcinoid tumors is the GI (gastrointestinal) tract and the lungs. However, it can also be developed in pancreas, testicles, and ovaries. The increasing prevalence of the carcinoid tumor is expected to drive the market growth. According to the American Society of Clinical Oncology (ASCO) in 2016, approximately 8,000 adults in the US were diagnosed with a carcinoid tumor in their GI tract. Moreover, it was also estimated that each year approximately 4,000 adults in the US are diagnosed with a carcinoid tumor in their lung. Moreover, growing geriatric population along with rising healthcare expenditure is likely to boost the market growth during the forecast period. However, lack of awareness, high treatment cost and related side effects may hamper the market growth during the forecast period. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4813 

Segmentation

The global carcinoid tumor market is segmented on the basis of site, diagnosis, treatment, and end users.

On the basis of the site, the market is segmented into gastrointestinal, lung, and others. Furthermore, the gastrointestinal segment is sub-segmented into rectum, small intestine, appendix, and others. Lung segment is sub-segmented into typical, atypical, and others.

On the basis of the diagnosis, the market is segmented into serology, imaging, biopsy, and others. The serology segment is sub-segmented into blood test, urine test, molecular test, and others. The imaging segment is sub-segmented into X-ray, CT scan, PET scan, and others.

On the basis of the treatment, the market is segmented into surgery, chemotherapy, radiotherapy, and others. The surgery segment is sub-segmented into local excision, radiofrequency ablation (RFA), and others.

On the basis of the end users, the market is segmented into hospitals & clinics, academic institutes, research organization, and others.

Regional Analysis

America dominates the global carcinoid tumor market owing to a well-developed healthcare sector and huge patient population. Apart from this, increasing healthcare expenditure and presence of developed economies like the U.S. and Canada within the region have boosted the growth of the market in America.

Europe is the second leading market across the globe, which is followed by Asia Pacific owing to availability of funds for research, huge patient population, and strong government support for research & development. According to the National Health Service in 2015, each year about 1,200 people are diagnosed with carcinoid tumor in the UK.

Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies like India and China, which have rising healthcare expenditure. Moreover, favorable governmental policies and the presence of huge opportunity in the untapped market within the region are likely to fuels the market growth during the forecast period. 

On the other hand, the Middle East & Africa holds the least share in the global carcinoid tumor market due to presence of poor economy, especially, in Africa region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. The presence of developed economies like Qatar, Saudi Arabia, Dubai, and others within the region fuels the market growth.

Key Players

Some of the key players in the global carcinoid tumor market are Novartis AG (Europe), Amgen Inc. (U.S.), Boehringer Ingelheim GmbH (Europe), AVEO Pharmaceuticals, Inc. (U.S.), Chiasma, Inc. (U.S.), Aegis Therapeutics, LLC (U.S.), CRINETICS PHARMACEUTICALS (U.S.), Delcath Systems Inc. (U.S.), Exelixis, Inc. (U.S.), and others.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/carcinoid-tumor-market-4813 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

 

The Pharmacogenomics Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

 

Market Highlights

Pharmacogenomics defines how genes can affect a person’s response to drugs. Pharmacogenomics is predicted to treat a wide range of health problems including cardiovascular diseases, Alzheimer disease, cancer, HIV/AIDS, and asthma, in near future. The growing biotech industry boosts the market growth. According to the Organization for Economic Co-operation and Development in 2017, biotech R&D in the business enterprise sector was 11.3%, and 9.4% of total business enterprise R&D, for U.S. and France respectively in 2014. Moreover, in 2016, according to the BIOCOM AG, the total turnover for the Germany based biotech companies was USD 3.7 billion. Moreover, rising healthcare expenditures followed by increasing interest for customized drugs will drive the market growth. However, lack of awareness and consistency in pharmacogenomics products will restrain the market growth during the forecasted period. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1177 

The global pharmacogenomics market is expected to grow at a ~CAGR of 5.8% during the forecasted period,

Segmentation

The global pharmacogenomics market is segmented on the basis of technology, application, and end user.

On the basis of technology, the market is segmented into microarray, sequencing, polymerase chain reaction, and others. The sequencing segment is sub-segmented into Sanger sequencing, pyrosequencing, next-generation sequencing, and others. On the basis of application, the market is segmented into oncology, cardiology, neurological disorders, and others. The oncology segment, by technology, is sub-segmented into breast cancer, lung cancer, and others. On the basis of end users, the market is segmented into hospitals, research organizations, academic institute, and others

Regional Analysis

America dominates the global pharmacogenomics market owing to a well-developed healthcare sector. Moreover, the presence of developed economies and rising number of patients suffering from cardiovascular diseases have boosted the growth of the market in America. In 2016, according to the Centres for Diseases Control and Prevention in the U.S., heart disease was the leading cause of death for both men and women 

Europe is the second largest pharmacogenomics market, followed by the Asia Pacific region. Availability of funds for research and development along with government support within the region will drive the market growth during the forecasted period. 

Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies like India and China and presence of huge opportunities in the market drives the market. According to the Indian Brand Equity Foundation in 2016, the Indian biotech industry is estimated to reach USD 100 billion by 2025 from USD 7 billion in 2015 with a CAGR of 30.46%. 

On the other hand, the Middle East & Africa has the least share in the global pharmacogenomics market due to presence of poor economy and stringent government policies especially in Africa region. The majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.

Key Players

The key players for the global pharmacogenomics market are Myriad Genetics, Inc. (U.S.), 23andMe, Inc. (U.S.), Pathway Genomics (U.S.), GeneTech (U.S.), GeneDx. (U.S.), Future Science Group (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Assurex Health, Inc. (U.S.), and others   

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/pharmacogenomics-market-1177

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Companion Animal Healthcare Market Worldwide Key Players Forecasts By Revenue, Growth Rate Till 2023

 

Market Highlights

Companion animals are pets reared by most of the people across the globe. They become an asset in the terms of providing protection to a person, property or workplace. Companion animal market is increasing due to an increase in number of people having pets, change in the way of providing care to the pets and awareness regarding spread of zoonotic diseases. Moreover, the financial improvement and related increments in disposable income, longer life expectancy for companion animals are some factors that influence the growth of companion animal healthcare market. Global companion animal healthcare market is expected to reach USD 20 billion by 2023 at a CAGR of 9.6% during forecast period 2017 to 2023.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1168 

Global companion animal healthcare market segmentation:

Global Companion animal healthcare market has been segmented on the basis product which includes feed additives, pharmaceuticals and vaccines. Feed additives can be divided into categories namely nutritional feed additives and medicinal feed additives. Nutritional feed additives include proteins, minerals and vitamins and medicinal feed additives include hormones, enzymes, immune-modulators, probiotics and prebiotics and others. Pharmaceutical products mainly comprise of anti-infectives, antibiotics and anti-inflammatories. The market is also segmented on the basis of diagnostic tests which include diagnostic imaging, immunodiagnostic tests, molecular diagnostics and other tests. End users are veterinary hospitals, veterinary clinics and home care.

Regional analysis

Globally, America accounts for the largest market share.  America consists of two regions namely North America and South America. Rising awareness about animal health, availability of wide range of products for animal health, increase in focus on food safety and increase in number of people having pets drive this market. Alarming occurrences of zoonotic diseases also affect the growth of this market. Collaborations, mergers and acquisition strategies applied by major market players drive this market in North America. After Americas, Europe is the second largest market for companion animal healthcare. While Asia Pacific a positive growth in this market. Increased awareness regarding animal cruelty and ideologies towards animals are some of the major factor driving the growth of this market in Asia Pacific.

The market shows a slow growth in Middle East & Africa. Middle East & African market for companion animal healthcare also shows high growth opportunities due financial improvement and related increments in disposable income.

Key players in the market

Key players in companion animal healthcare market are: Zoetis Animal Healthcare (U.S.), Merck Co., Inc. (U.S.), Elanco Animal health (U.S.), Merial (France), Bayer Animal Health (Germany), Ceva Animal Healthcare (U.K), Virbac Animal Healthcare (France), Vetoquinol S.A. (France), Perrigo Company plc (Ireland), Boehringer Ingelheim (Germany) and others.

Zoetis Animal Healthcare is a global animal healthcare company providing wide range of products for animal care. It provides specific products for dogs, cats and horses. Apoquel, Cerenia, Convenia, Cytopoint, Palladia, Rimadyl are the products for dogs.

FOR MORE DETAILS – https://www.marketresearchfuture.com/reports/companion-animal-healthcare-market-1168 

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Worldwide Cerebrospinal Fluid Management Devices Market Ready To Set Outstanding Growth From 2020 To 2027

 Cerebrospinal Fluid Management Devices Market Analysis

The Cerebrospinal Fluid Management (CSF) Devices market is growing pervasively. The market growth attributes to the rising prevalence of various neurological diseases and disorders. CSF devices are primarily used in the treatment of hydrocephalus, a condition that refers to the accumulation of cerebrospinal fluid (CSF) in the brain.  Hence, the growing awareness for this condition is also a significant factor that, along with the adoption of advanced and minimally invasive treatment procedures, escalates the market growth to furthered height.

According to Market Research Future (MRFR), the global cerebrospinal fluid management (CSF) devices market is estimated to grow at approx. 4.5% CAGR during the forecast period (2018 -2023). Also, factors such as the growing geriatric population and awareness about hydrocephalus propel the growth of the market. Simultaneously, the increasing prevalence of hydrocephalus in children boosts the market growth to an extent. Also, several risk factors leading to neurological disorders are creating enormous market demand.

Get a FREE Sample with Complete TOC By Considering the COVID-19 impact on Global Market @ https://www.marketresearchfuture.com/sample_request/7196

Additionally, increasing government funding and programs to support the R&D activities required for the development of CSF devices substantiate market growth. Furthermore, technological advances in the field of smart and connected devices, alongside the uses of some ubiquitous technologies such as Artificial Intelligence (AI) and the Internet of Things (IoT) to better diagnostic and treatment methods foster the market growth.

Conversely, factors such as the lack of trained professionals and side-effects associated with the treatment are projected to obstruct the market growth in years to come. Also, the high cost of CSF devices and lack of awareness for Hydrocephalus condition, act as major growth impeders for the market growth, especially in underdeveloped regions. Nevertheless, product launches of cost-competitive CSF devices would support the market growth throughout the anticipated period, filling the demand-supply gap.

Global CSF Devices Market- Segments

The report is segmented into four dynamics;

By Product: Shunts (Ventriculoperitoneal (VP), Ventriculoatrial (VA), Lumboperitoneal (LP), Ventriculopleural (VPL), others), Valve (Fixed and Adjustable), External Drainage Systems (External Ventricular Drainage (EVD) Systems, Lumbar Drainage (LD) Systems, others), and others.

By Age Group: Pediatric, Adult, and Geriatric.

By End User: Hospitals, Ambulatory Settings, Clinics, Research & Academic Institutes, and others.

By Regions:  Americas, Europe, Asia Pacific, and Rest-of-the-World.

Cerebrospinal Fluid Management Devices Market – Regional Analysis

North America dominates the global cerebrospinal fluid management devices market. The largest market share attributes to the strong presence of notable market players and a large base of patients suffering from various neurological diseases & disorders. Besides, the early uptake of technologically advanced medical devices for the treatment of the growing prevalence of neurological disorders in children and adults drive the regional market growth.

Furthermore, factors such as the increasing R&D support by the governments and high expenditures in neurological care substantiate the market growth. The North American CSF devices market is estimated to retain its dominance over the global market throughout the forecast period.

Europe stands second in the global cerebrospinal fluid management devices market. Growth is driven by rising research and development investments and increasing technological advancements. Moreover, factors such as the increasing incidents of neurological disorders and focus on the development of advent diagnostic devices contribute to the regional market growth. Also, rising government support for R&D activities, alongside the increasing numbers of specialty services offered by various healthcare providers in the region fosters market growth.

Asia Pacific is an emerging market for cerebrospinal fluid management devices. Factors such as increased healthcare expenditures and rising cases of hydrocephalus drive the growth of the regional market. Additionally, growing occurrences of neurological disorders in the region, fuel the market growth.  Furthermore, augmenting demand for quality devices to treat neurological diseases & disorders and penetration of healthcare technology provide impetus to the regional market growth, leading to increasing the uptake of CSF devices.

Global Cerebrospinal Fluid Management Devices Market- Competitive Analysis

Highly competitive, the CSF devices market appears fragmented, with a large number of players in the market churning the competition. Increasing incidences of drug resistance have opened doors for new entrants and leaders’ development of new devices and opportunities. The rise of spurious and counterfeit devices has reduced the total market revenues, displacing standard devices off the market.

Cerebrospinal Fluid Management Devices Market Major Players:

Players leading the CSF devices market include Integra LifeSciences Holdings Corporation, Medtronic plc, B. Braun Melsungen AG, Spiegelberg GmbH & Co. KG, DePuy Synthes, SOPHYSA, Dispomedica GmbH, Natus Medical Incorporated, Delta Surgical Limited, Moller Medical GmbH, Argi Grup, G. SURGIWEAR LTD., BeckerSmith Medical, Inc., and Wellong Instruments Co., Ltd., among others.

Cerebrospinal Fluid Management Devices Industry/Innovations/Related News:

May 15, 2020 —- Aesculap, Inc. (Germany), a leading medical device manufacturer, and its partner The Christoph Miethke GmbH & Co. KG (MIETHKE – Germany), launched the M.blue valve, the latest generation of Hydrocephalus valve technology in the US. The unique gravitational technology is integrated with a fixed differential pressure unit in one valve, allowing for a simple, position-dependent solution.

Aesculap, Inc. is a B. Braun company, the world’s largest manufacturers of surgical instruments, medical devices, and sterilization container systems. The MIETHKE develops, produces, and distributes innovative neurosurgical products for the treatment of hydrocephalus. The partnership demonstrates an impactful collaborative effort to bring better Hydrocephalus solutions to patients, such as the new M.blue valve.

Obtain Premium Research Report Details, Considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/cerebrospinal-fluid-management-devices-market-7196

COVID-19 Diagnostics Market Overview By Trends, Industry Top Manufactures, Size, Industry Growth Analysis & Forecast Till 2027

 Market Highlights

Global COVID-19 Diagnostics Market is expected to register a CAGR of 6.28% during the forecast period, with a market value of USD 96,293.9 Million by 2027. COVID-19 is one of the most harmful infectious diseases that is caused by a coronavirus. Wuhan, China was the first place to experience the disease’s outbreak, followed by Europe, and then to the other countries globally by infected people.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/9710 

Segment Analysis

Global COVID-19 Diagnostics Market has been segmented by Type, Technology, and End Users. The market, based on type, has been bifurcated into molecular tests and serology tests. On the basis of technology, the market has been bifurcated into RT-PCR, isothermal amplification, CRISPR, ELISA, hybridization, and others.

Based on End User, the COVID-19 diagnostics market has been segregated into hospitals, public health labs, private or commercial labs, and others.

Regional Analysis

Global COVID-19 Diagnostics Market, based on region, has been divided into the Europe, Americas, Asia-Pacific, and the Middle East & Africa.

The Europe is likely to dominate the global COVID-19 diagnostics market. This can be attributed to the high COVID-19 morbidity and mortality observed among residents in long-term care facilities (LTCF) in European Union (EU) and European Economic Area (EEA) pose a major challenge for disease prevention and control in such settings, which raises the demand for the wide availability of diagnostics for immediate detection of COVID-19 cases. According to European Centre for Disease Control and Prevention, 157 312 deaths in the EU/EEA and the UK as of 19 May 2020 were reported. Moreover, the support from public & private organizations in tackling COVID-19 is also expected to drive market growth in the region.

The American market for COVID-19 diagnostics is expected to be the second largest during the forecast period. Rising product launches by major players and ongoing public and private organizations’ efforts to control the spread of the virus is anticipated to drive the market growth. For instance, in March 2020, the US FDA issued a EUA for a molecular point of care test kit by Abbott for the rapid detection of COVID-19. Furthermore, the increasing numbers of corona virus-positive cases also act as a driving factor and support market growth.

Asia-Pacific is estimated to be the fastest-growing market. With an increasing number of cases, governments across the Asia-Pacific countries are exploring the opportunities of allowing private laboratories to ramp up testing, which is boosting the market growth. For instance, In India, the Indian Council of Medical Research (ICMR) has approved 51 private laboratories for COVID-19 testing on March 31, 2020. Moreover, the increasing number of COVID-19 cases is also driving the market growth.

The market in the Middle East & Africa is expected to witness steady growth. Countries such as Kuwait, the UAE, and Saudi Arabia are likely to show steady growth due to increasing COVID-19 cases and rising initiatives by governments to improve patient care.

Key Players

MRFR recognizes the following companies as the Key Players in the Global COVID-19 Diagnostics Market— Becton, Dickinson & Company (US), Bio-Rad Laboratories (US), Danaher Corporation (US), Abbott (US), F. Hoffmann-La Roche Ltd (Switzerland), Biomerieux SA (France), Genmark Diagnostics (US), Thermo Fisher Scientific (US), Qiagen (Germany), and Siemens AG (Germany).

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/covid-19-diagnostics-market-9710

Healthcare Personal Protection Equipment Industry Overview By Growth Factors, Product Chain Value, Competitors Analysis And Forecast 2027

 Global Healthcare Personal Protection Equipment Market is expected to cross USD 10.116 Billion by 2027 at a CAGR of 9.17%.  

Market Synopsis

Personal Protective Equipment (PPEs) are protective gear designed to safeguard the health of workers by minimizing the exposure to a biological agent. It is one of the necessary tools in preventing transmission of infectious diseases not only in treatment centers but also in various activities, e.g. cleaning, waste management and safe burials, and community care related to the outbreak. Components of PPE are goggles, face-shield, mask, gloves, coverall/gowns (with or without aprons), head cover, shoe cover, and others.

Impact of Covid-19 Outbreak on Healthcare Personal Protection Equipment Market

Healthcare Personal Protection Equipment (PPE) are protective gears that are designed to safeguard the workers by minimizing the exposure to a biological agent. PPE helps healthcare workers to fight against novel coronavirus (COVID-19). The World Health Organization (WHO) has recommended several governments worldwide to increase the production of masks, gloves, respirators, and coveralls/gowns. It also recommended that PPE manufacturers must increase their production by 40% and prioritizing their orders to countries with a high demand-supply gap.   

Several countries, including India, have considered importing PPE kits to meet its requirements from China, Singapore, and South Korea. Although a tender was rolled out last week by the government’s nodal procurement agency HLL Lifecare, the government has chosen not to wait for the bids to be released, rather than source it from other countries. As of the 3rd week of April, the coronavirus (COVID-19) pandemic crossed two million cases globally. The increasing demand for hand protection, respiratory protection, and protective clothing in the healthcare industry to ensure people’s safety during the ongoing COVID-19 pandemic is expected to boost the demand for PPE.  Furthermore, the increasing government initiatives to facilitate the import of PPE is expected to drive the market growth. For instance, in March 2020, in response to the COVID-19 outbreak, the Food and Drug Administration (FDA) initiated numerous steps to improve the US stocks of PPE. A few of its measures include adjustments in import screening, flexibility to manufacturers, and creation of special mailbox service, among other provisions.

We have observed the massive impact of novel coronavirus on people’s lives over the last five months. It has also impacted various industries across the globe, eventually affecting the global economy. Some industries have experienced negative growth, whereas some industries have experienced tremendous demand and have generated massive revenues in this period. Covid 19 Impact on Healthcare Personal Protection Equipment market is the one of the positive impact sector on global industry

Healthcare Personal Protection Equipment Market Influencer

PPE helps healthcare workers to fight against novel coronavirus (COVID-19). The World Health Organization (WHO) has recommended the governments across the world to increase the production of masks, gloves, respirators, and coveralls/gowns. It also recommended that PPE manufacturers must increase their production by 40% and prioritizing their orders to the countries with a high demand-supply gap.

Market Drivers

• As of the 3rd week of April, coronavirus (COVID-19) pandemic crossed 2 million cases globally. The increasing demand for hand protection, respiratory protection, and protective clothing in the healthcare industry to ensure the people’s safety during the ongoing COVID-19 pandemic is expected to boost the demand for Personal Protective Equipment (PPE).
• Rapid technological advancements in the field of surgery such as High-Reliability Organizing (HRO), technical advancements, and standardizing procedures are expected to have a positive impact on the hospital sector, thereby impacting the demand for personal protective equipment positively.
• Increasing government initiatives to facilitate the import of personal protective equipment is expected to drive the market growth. For instance, in March 2020, in response to the COVID-19 outbreak, the Food and Drug Administration (FDA) initiated numerous steps to improve US stocks of personal protective equipment. The measures include adjustments in import screening, flexibility to manufacturers, and creation of special mailbox service, among other provisions.
• The emergence of local PPE manufacturers, increasing end user demand, and the rising production of cost-effective and integrated PPE is expected to boost the market growth. For instance, in India, the Union Textiles Ministry and the Health Ministry has said the government is augmenting the supplies of personal protective equipment (PPEs), including body coveralls, N-95 masks and 2-ply/3-ply surgical masks required for healthcare professionals dealing with COVID-19 cases. Furthermore, more than 130 Australian companies have responded to an urgent call to dramatically boost the manufacturing of face masks, gowns, and gloves to deal with the COVID-19 crisis.

Market Restraints

• The current global stockpile of PPE is inadequate to handle the existing and expected cases in different parts of the world, particularly for medical masks and respirators. The supply of gowns and goggles is also expected to be insufficient as the disease is spread. Surging global demand is not only driven by the increasing number of COVID-19 cases but also by misinformation, hoarding, and panic buying. The lockdown in a significant portion of the world is hampering the manufacturing of PPE.
• The high cost of raw materials (specialized clothing and other related products) is hindering the demand for PPEs in economically weak countries.

Healthcare Personal Protection Equipment Market Segmentation

By Product

• Protective Clothing: The protective clothing is further segmented into coveralls, gowns, and others. Coverall/gowns are designed to protect the torso of healthcare providers from exposure to the virus.
• Respiratory Protection: Respiratory protection is bifurcated into surgical masks, respirator masks, and others. The healthcare professionals are recommended to use surgical N95 respirators or medical respirators to protect them from the direct exposure to the COVID-19 virus.
• Head, Eye, and Face Protection: The largest segment. To prevent exposure of the eye and face from the virus, goggles or a face shield should be considered. High risk of COVID-19 and other infections through nose, eyes, and ears is among the primary reason driving the growth for this segment. The goggles must fit the contours of the user’s face and are compatible with the respirator. The use of face shields/ goggles is an integral part of standard and contact precautions for the people most at risk of COVID-19 infection.
• Protective Footwear: The use of protective footwear such as washable and disposable footwear is essential to avoid self-contamination.
• Hand protection: Hand protection is further sub-segmented into general-purpose, chemical handling, sterile gloves, and surgical. The rising awareness about hygiene and prevention from the transmission of pathogens in healthcare facilities is increasing the demand for medical gloves.
• Others

By End Use

• Hospitals & Clinics: The largest segment and expected to grow at the highest CAGR during the forecast period. The rising awareness regarding the hand protection during a viral outbreak is increasing the demand for PPEs in hospitals.
• Ambulatory Surgical Centers: The increasing number of patients visiting surgical centers is facilitating the demand for PPEs in ambulatory surgical centers.
• Academic and Research Institutes: PPEs are very effective in minimizing occupational injuries, accidents, and other hazards which otherwise result in substantial manpower and financial losses. The use of basic PPE is a must in research institutes as they protect from skin contact and contamination.
• Diagnostic Laboratories: The use of protective equipment is necessary for diagnostic laboratories to protect healthcare workers from specific hazards and hazardous materials.
• Others

By Region

• Americas: The largest regional market. The increasing government initiatives and rising concerns in terms of health and safety of healthcare professionals is boosting the demand for the same. Moreover, the rising prevalence of COVID-19 infection is majorly contributing to the growth of this region.
• Europe: The healthcare market in Northern European economies, such as Germany, U.K., and Sweden, is expected to exhibit an increase in healthcare expenditure, thereby leading to the growth in production as well as the consumption of medical devices and products.
• Asia-Pacific: The fastest-growing regional market. Emerging market players in the region, technological advancements, rising focus of government towards healthcare facilities, and high target population in the region are among the key factors driving the market growth in the region.   
• Middle East & Africa: The high penetration of personal protective equipment in developed healthcare industries of UAE, South Africa is expected to drive the growth of the market in this region.

 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/healthcare-personal-protection-equipment-market-9594